Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases

Figure 1 Selection of hepatocellular carcinoma patients. ¹Not-univocal: Reports/records repeated/belonging for/to patients already recruited. US: Ultrasound; CEUS: Contrast enhanced ultrasound; CT: Computed tomography; MRI: Magnetic resonance imaging; HCC: Hepatocellular carcinoma.

Figure 2 Different liver disease etiologies and distribution of Barcelona Clinic Liver Cancer stages in the first (I) period (2000-2005) and in the second (II) period (2005-2010). A: Different liver disease etiologies; B: Distribution of Barcelona Clinic Liver Cancer (BCLC) stages. HCV: Hepatitis C virus; HBV: Hepatitis B virus.

Figure 3 Treatment distribution in the two different periods and different Barcelona Clinic Liver Cancer stages. A: Treatment distribution comparing the two 5-year periods (2000-2005 vs 2005-2010); B: Distribution of treatments in different Barcelona Clinic Liver Cancer (BCLC) stages. TACE: Trans-arterial chemoembolization; RF/PEI: Radiofrequency/percutaneous ethanol injection.

Figure 4 Survival in the two different periods, different Barcelona Clinic Liver Cancer stages. A: Survival in the two different periods, I = (2000-2005) vs II (2005-2010), ^bP < 0.01 vs II period; B: Survival in different Barcelona Clinic Liver Cancer stages.

Figure 5 Survival according to treatment. OLT: Orthotopic liver transplantation; TACE: Trans-arterial chemoembolization.